细胞铁死亡调控机制及其在乳腺癌治疗中的意义

doi:10.3760/cma.j.cn371439-20191206-00039

摘要/Abstract

摘要：

乳腺癌是起源于乳腺上皮组织的恶性肿瘤,铁死亡是一种新发现的、不同于细胞凋亡和坏死的细胞程序性死亡方式。目前研究表明,脂质过氧化物在细胞内的堆积这一铁死亡诱发的关键过程可由多种机制诱发,铁死亡的调控与乳腺癌的发生、发展密切相关,药物诱导乳腺癌细胞铁死亡是颇具潜力与价值的研究方向。

关键词: 乳腺肿瘤, 活性氧, 铁死亡

Abstract:

Breast cancer is a malignant tumor originating from breast epithelial tissue. Ferroptosis is a novel type of programmed cell death which differs from apoptosis and necrosis. Research found that the accumulation of lipid peroxides in cells, a crucial process of ferroptosis, can be induced by multiple mechanisms. The ferroptosis regulation is closely related to the occurrence and development of breast cancer, and it induced by drugs is a potential and valuable research direction in breast cancer.

Key words: Breast neoplasms, Reactive oxygen species, Ferroptosis

徐一月, 赵少荣, 刘晶晶, 张瑾. 细胞铁死亡调控机制及其在乳腺癌治疗中的意义[J]. 国际肿瘤学杂志, 2020, 47(6): 372-376.

Xu Yiyue, Zhao Shaorong, Liu Jingjing, Zhang Jin. Mechanisms of ferroptosis and its significance in breast cancer therapy[J]. Journal of International Oncology, 2020, 47(6): 372-376.

参考文献 51

[1]	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. Cell, 2012,149(5):1060-1072. DOI: 10.1016/j.cell.2012.03.042. doi: 10.1016/j.cell.2012.03.042
[2]	Arosio P, Elia L, Poli M. Ferritin, cellular iron storage and regulation[J]. IUBMB Life, 2017,69(6):414-422. DOI: 10.1002/iub.1621. doi: 10.1002/iub.1621 pmid: 28349628
[3]	Toyokuni S, Ito F, Yamashita K, et al. Iron and thiol redox signaling in cancer: an exquisite balance to escape ferroptosis[J]. Free Radic Biol Med, 2017,108:610-626. DOI: 10.1016/j.freeradbiomed.2017.04.024. doi: 10.1016/j.freeradbiomed.2017.04.024 pmid: 28433662
[4]	Lim JKM, Delaidelli A, Minaker SW, et al. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance[J]. Proc Natl Acad Sci U S A, 2019,116(19):9433-9442. DOI: 10.1073/pnas.1821323116. doi: 10.1073/pnas.1821323116 pmid: 31000598
[5]	Xu T, Ding W, Ji X, et al. Molecular mechanisms of ferroptosis and its role in cancer therapy[J]. J Cell Mol Med, 2019,23(8):4900-4912. DOI: 10.1111/jcmm.14511. doi: 10.1111/jcmm.14511 pmid: 31232522
[6]	Gao M, Yi J, Zhu J, et al. Role of mitochondria in ferroptosis[J]. Mol Cell, 2019,73(2):354-363.e3.DOI: 10.1016/j.molcel.2018.10.042. doi: 10.1016/j.molcel.2018.10.042 pmid: 30581146
[7]	Zhang K, Wu L, Zhang P, et al. miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma[J]. Mol Carcinog, 2018,57(11):1566-1576. DOI: 10.1002/mc.22878. doi: 10.1002/mc.22878 pmid: 30035324
[8]	Luo M, Wu L, Zhang K, et al. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma[J]. Cell Death Differ, 2018,25(8):1457-1472. DOI: 10.1038/s41418-017-0053-8. doi: 10.1038/s41418-017-0053-8 pmid: 29348676
[9]	Maiorino M, Conrad M, Ursini F. GPx4, lipid peroxidation, and cell death: discoveries, rediscoveries, and open issues[J]. Antioxid Redox Signal, 2018,29(1):61-74. DOI: 10.1089/ars.2017.7115. doi: 10.1089/ars.2017.7115 pmid: 28462584
[10]	Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication[J]. Free Radic Biol Med, 2019,133:144-152. DOI: 10.1016/j.freeradbiomed.2018.09.014. doi: 10.1016/j.freeradbiomed.2018.09.014 pmid: 30219704
[11]	Sui X, Zhang R, Liu S, et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer[J]. Front Pharmacol, 2018,9:1371. DOI: 10.3389/fphar.2018.01371. doi: 10.3389/fphar.2018.01371 pmid: 30524291
[12]	Imai H, Matsuoka M, Kumagai T, et al. Lipid peroxidation-dependent cell death regulated by GPx4 and rerroptosis[J]. Curr Top Microbiol Immunol, 2017,403:143-170. DOI: 10.1007/82_2016_508. doi: 10.1007/82_2016_508 pmid: 28204974
[13]	Fan Z, Wirth AK, Chen D, et al. Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis[J]. Oncogenesis, 2017,6(8):e371. DOI: 10.1038/oncsis.2017.65. doi: 10.1038/oncsis.2017.65 pmid: 28805788
[14]	Zimta AA, Cenariu D, Irimie A, et al. The role of Nrf2 activity in cancer development and progression[J]. Cancers (Basel), 2019,11(11). E1755. DOI: 10.3390/cancers11111755.
[15]	Horniblow RD, Bedford M, Hollingworth R, et al. BRAF mutations are associated with increased iron regulatory protein-2 expression in colorectal tumorigenesis[J]. Cancer Sci, 2017,108(6):1135-1143. DOI: 10.1111/cas.13234. doi: 10.1111/cas.13234 pmid: 28281325
[16]	Guo J, Xu B, Han Q, et al. Ferroptosis: a novel anti-tumor action for cisplatin[J]. Cancer Res Treat, 2018,50(2):445-460. DOI: 10.4143/crt.2016.572. doi: 10.4143/crt.2016.572 pmid: 28494534
[17]	Lin X, Liao J, Yang Z, et al. Inhibition of cisplatin-resistant head and neck squamous cell carcinoma by combination of Afatinib with PD0325901, a MEK inhibitor[J]. Am J Cancer Res, 2019,9(6):1282-1292. pmid: 31285959
[18]	Ruiu R, Rolih V, Bolli E, et al. Fighting breast cancer stem cells through the immune-targeting of the xCT cystine-glutamate antiporter[J]. Cancer Immunol Immunother, 2019,68(1):131-141. DOI: 10.1007/s00262-018-2185-1. doi: 10.1007/s00262-018-2185-1 pmid: 29947961
[19]	Masaldan S, Clatworthy SAS, Gamell C, et al. Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis[J]. Redox Biol, 2018,14:100-115. DOI: 10.1016/j.redox. 2017.08.015. doi: 10.1016/j.redox.2017.08.015 pmid: 28888202
[20]	Hao S, Yu J, He W, et al. Cysteine dioxygenase 1 mediates erastin-induced ferroptosis in human gastric cancer cells[J]. Neoplasia, 2017,19(12):1022-1032. DOI: 10.1016/j.neo.2017.10.005. doi: 10.1016/j.neo.2017.10.005 pmid: 29144989
[21]	Gai C, Yu M, Li Z, et al. Acetaminophen sensitizing erastin-induced ferroptosis via modulation of Nrf2/heme oxygenase-1 signaling pathway in non-small-cell lung cancer[J]. J Cell Physiol, 2020,235(4):3329-3339. DOI: 10.1002/jcp.29221. doi: 10.1002/jcp.29221 pmid: 31541463
[22]	Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target[J]. Cancer Cell, 2013,24(4):450-465. DOI: 10.1016/j.ccr.2013.08.020. doi: 10.1016/j.ccr.2013.08.020
[23]	Geng N, Shi BJ, Li SL, et al. Knockdown of ferroportin accelerates erastin-induced ferroptosis in neuroblastoma cells[J]. Eur Rev Med Pharmacol Sci, 2018,22(12):3826-3836. DOI: 10.26355/eurrev_201806_15267. doi: 10.26355/eurrev_201806_15267 pmid: 29949159
[24]	Yu M, Gai C, Li Z, et al. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells[J]. Cancer Sci, 2019,110(10):3173-3182. DOI: 10.1111/cas.14181. doi: 10.1111/cas.14181 pmid: 31464035
[25]	Yu H, Yang C, Jian L, et al. Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor[J]. Oncol Rep, 2019,42(2):826-838. DOI: 10.3892/or.2019.7189. doi: 10.3892/or.2019.7189 pmid: 31173262
[26]	Ma S, Henson ES, Chen Y, et al. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells[J]. Cell Death Dis, 2016,7:e2307. DOI: 10.1038/cddis.2016.208. doi: 10.1038/cddis.2016.208 pmid: 27441659
[27]	Ma S, Dielschneider RF, Henson ES, et al. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells[J]. PLoS One, 2017,12(8):e0182921. DOI: 10.1371/journal.pone.0182921. doi: 10.1371/journal.pone.0182921 pmid: 28827805
[28]	Nagpal A, Redvers RP, Ling X, et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2^+ve breast cancer metastasis[J]. Breast Cancer Res, 2019,21(1):94. DOI: 10.1186/s13058-019-1177-1. doi: 10.1186/s13058-019-1177-1 pmid: 31409375
[29]	Mbaveng AT, Bitchagno GTM, Kuete V, et al. Cytotoxicity of ungeremine towards multi-factorial drug resistant cancer cells and induction of apoptosis, ferroptosis, necroptosis and autophagy[J]. Phytomedicine, 2019,60:152832. DOI: 10.1016/j.phymed.2019.152832. doi: 10.1016/j.phymed.2019.152832 pmid: 31031043
[30]	Shan Z, Wei Z, Shaikh ZA. Suppression of ferroportin expression by cadmium stimulates proliferation, EMT, and migration in triple-negative breast cancer cells[J]. Toxicol Appl Pharmacol, 2018,356:36-43. DOI: 10.1016/j.taap.2018.07.017. doi: 10.1016/j.taap.2018.07.017 pmid: 30030096
[31]	Pizzamiglio S, De Bortoli M, Taverna E, et al. Expression of iron-related proteins differentiate non-cancerous and cancerous breast tumors[J]. Int J Mol Sci, 2017, 18(2). pii: E410. DOI: 10.3390/ijms18020410. doi: 10.3390/ijms18020444 pmid: 28230770
[32]	Park E, Chung SW. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation[J]. Cell Death Dis, 2019,10(11):822. DOI: 10.1038/s41419-019-2064-5. doi: 10.1038/s41419-019-2064-5 pmid: 31659150
[33]	Tang M, Chen Z, Wu D, et al. Ferritinophagy/ferroptosis: iron-related newcomers in human diseases[J]. J Cell Physiol, 2018,233(12):9179-9190. DOI: 10.1002/jcp.26954. doi: 10.1002/jcp.26954 pmid: 30076709
[34]	Gryzik M, Srivastava A, Longhi G, et al. Expression and characterization of the ferritin binding domain of nuclear receptor coactivator-4 (NCOA4)[J]. Biochim Biophys Acta Gen Subj, 2017,1861(11 Pt A):2710-2716. DOI: 10.1016/j.bbagen.2017.07.015. doi: 10.1016/j.bbagen.2017.07.015 pmid: 28754384
[35]	Zhang Z, Yao Z, Wang L, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells[J]. Autophagy, 2018,14(12):2083-2103. DOI: 10.1080/15548627.2018.503146. doi: 10.1080/15548627.2018.1503146 pmid: 30081711
[36]	Yang WS, Kim KJ, Gaschler MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis[J]. Proc Natl Acad Sci U S A, 2016,113(34):e4966-e4975. DOI: 10.1073/pnas.1603244113. doi: 10.1073/pnas.1603244113 pmid: 27506793
[37]	Jarc E, Kump A, Malavasic P, et al. Lipid droplets induced by secreted phospholipase A2 and unsaturated fatty acids protect breast cancer cells from nutrient and lipotoxic stress[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2018,1863(3):247-265. DOI: 10.1016/j.bbalip.2017.12.006. doi: 10.1016/j.bbalip.2017.12.006 pmid: 29229414
[38]	Kuwata H, Nakatani E, Shimbara-Matsubayashi S, et al. Long-chain acyl-CoA synthetase 4 participates in the formation of highly unsaturated fatty acid-containing phospholipids in murine macrophages[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019,1864(11):1606-1618. DOI: 10.1016/j.bbalip.2019.07.013. doi: 10.1016/j.bbalip.2019.07.013 pmid: 31376475
[39]	Jalil A, Bourgeois T, Ménégaut L, et al. Revisiting the role of LXRs in PUFA metabolism and phospholipid homeostasis[J]. Int J Mol Sci, 2019, (15). pii: E3787. DOI: 10.3390/ijms20153787. doi: 10.3390/ijms20153824 pmid: 31387280
[40]	Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017,13(1):91-98. DOI: 10.1038/nchembio.2239. doi: 10.1038/nchembio.2239 pmid: 27842070
[41]	Wu X, Zhi F, Lun W, et al. Baicalin inhibits PDGF-BB-induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR-3595/ACSL4 axis[J]. Int J Mol Med, 2018,41(4):1992-2002. DOI: 10.3892/ijmm.2018.3427. doi: 10.3892/ijmm.2018.3427 pmid: 29393361
[42]	Park S, Oh J, Kim M, et al. Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis[J]. Anim Cells Syst (Seoul), 2018,22(5):334-340. DOI: 10.1080/19768354.2018.1512521. doi: 10.1080/19768354.2018.1512521
[43]	Magtanong L, Ko PJ, To M, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state[J]. Cell Chem Biol, 2019,26(3):420-432, e9. DOI: 10.1016/j.chembiol.2018.11.016. doi: 10.1016/j.chembiol.2018.11.016 pmid: 30686757
[44]	Xie Y, Zhu S, Song X, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity[J]. Cell Rep, 2017,20(7):1692-1704. DOI: 10.1016/j.celrep.2017.07.055. doi: 10.1016/j.celrep.2017.07.055 pmid: 28813679
[45]	Kaiser AM, Attardi LD. Deconstructing networks of p53-mediated tumor suppression in vivo[J]. Cell Death Differ, 2018,25(1):93-103. DOI: 10.1038/cdd.2017.171. doi: 10.1038/cdd.2017.171 pmid: 29099489
[46]	Liu DS, Duong CP, Haupt S, et al. Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation[J]. Nat Commun, 2017,8:14844. DOI: 10.1038/ncomms14844. doi: 10.1038/ncomms14844 pmid: 28348409
[47]	Tarangelo A, Magtanong L, Bieging-Rolett KT, et al. P53 suppresses metabolic stress-induced ferroptosis in cancer cells[J]. Cell Rep, 2018,22(3):569-575. DOI: 10.1016/j.celrep.2017.12.077. doi: 10.1016/j.celrep.2017.12.077 pmid: 29346757
[48]	Aubrey BJ, Kelly GL, Janic A, et al. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?[J]. Cell Death Differ, 2018,25(1):104-113. DOI: 10.1038/cdd.2017.169. doi: 10.1038/cdd.2017.169 pmid: 29149101
[49]	Mao C, Wang X, Liu Y, et al. A G3BP1-interacting lncRNA promotes ferroptosis and apoptosis in cancer via nuclear sequestration of p53[J]. Cancer Res, 2018,78(13):3484-3496. DOI: 10.1158/0008-5472.CAN-17-3454. doi: 10.1158/0008-5472.CAN-17-3454 pmid: 29588351
[50]	Kawano Y, Iwama E, Tsuchihashi K, et al. CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: a target for treatment[J]. Lung Cancer, 2017,113:72-78. DOI: 10.1016/j.lungcan.2017.09.008. doi: 10.1016/j.lungcan.2017.09.008 pmid: 29110853
[51]	Xiong H, Wang C, Wang Z, et al. Intracellular cascade activated nanosystem for improving ER+ breast cancer therapy through attacking GSH-mediated metabolic vulnerability[J]. J Control Release, 2019,309:145-157. DOI: 10.1016/j.jconrel.2019.07.029. doi: 10.1016/j.jconrel.2019.07.029 pmid: 31348976